Archive
Proactive news snapshot: Wishbone Gold, SIMEC Atlantis Energy, Corero Network Security …
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 14 of 21
Wishbone Gold shares surge as Honduran joint venture receives license
A look at some of the top risers and fallers in London on Wednesday
Faron Pharmaceuticals provides insight on phase III trial
It has carried out a study involving 50 people which has shown its drug was formulated appropriately when administered in a phase III clinical trial
FTSE 100 closes higher Wednesday; Dow Jones up 1.3%
The UK's premier share index finished over 64 points higher at 6,765
Archive
Proactive news snapshot: Faron Pharma, Itaconix, Eco Atlantic Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Premier African shares rise as it signs restructuring framework agreement with KME
A look at some of the biggest risers and fallers in London on Wednesday
Faron convinced Traumakine still has potential as an ARDS treatment
Analysis of the phase III trial data suggests that ARDS patients with a certain genetic mutation responded particularly well to Traumakine
Archive
FTSE 100 closes lower as traders stay wary; Ashtead Group biggest faller
FTSE 250 was also down - closing around 58 points lower at 18,271
Archive
Interserve weak as Kier Group cash call comments spark concerns for constructors
A look at some of the London market's biggest risers and fallers on Monday
Archive
Small Cap Movers: Closing of Safestyle UK competition drama gives shareholders a lift
A look back at some of the more interesting from the junior market this week...
Faron's follow-up investigations may breathe new life into Traumakine development
"At this stage, it appears possible that unexpectedly high corticosteroid use in the INTEREST trial may have masked the treatment benefit of Traumakine in ARDS patients," said Dr Matti Karvonen, the chief medical officer of Faron
Faron Pharma: Making sense of the recent news flow
Context is everything when it comes to junior drugs stocks. However, the reaction to failure tends to be binary
Archive
Proactive news snapshot: Anglo Asian Mining, Mirada, Mosman Oil And Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Sirius Minerals advances, supermarkets Tesco, J Sainsbury, Morrison PLC rise
A look at some of the biggest risers and fallers in the London market Monday
FTSE 100 closes lower after lacklustre day; trade fears weigh
FTSE 100 closed down nearly two points on the day at 7,302
Faron Pharma boss “excited” to begin first in-human trial of Clevegen later this year
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
Archive
Proactive news snapshot: Bushveld Minerals, Nektan. Europa Metals …
A glance at some of the day's highlights from the Proactive Investors newswire
Anglo Asian Mining shares fly higher as it takes steps to identify new targets
A look at some of the top risers and fallers in London on Thursday
Faron Pharma boss “excited” to begin first in-human trial of Clevegen later this year
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
FTSE 100 finishes lower as BoE keeps rates on hold; sterling gains
The UK benchmark index of leading shares finished down nearly 32 points at 7,281